# This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

> **NCT04254471** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 313 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** AL3810
- **DRUG:** carboplatin + etoposide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04254471
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-14
- **Primary completion:** 2022-05-22
- **Final completion:** 2022-11-22
- **Target enrollment:** 313 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254471, "This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04254471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*